Show simple item record

dc.creatorGabrio, Andrea
dc.creatorGunsoy, Necdet B.
dc.creatorBaio, Gianluca
dc.creatorMartin, Alan
dc.creatorPaly, Victoria F.
dc.creatorRisebrough, Nancy
dc.creatorHalpin, David M. G.
dc.creatorSingh, Dave
dc.creatorWise, Robert A.
dc.creatorHan, MeiLan K.
dc.creatorMartinez, Fernando J.
dc.creatorCriner, Gerard J.
dc.creatorMartin, Neil
dc.creatorLipson, David A.
dc.creatorIsmalia, Afisi S.
dc.date.accessioned2024-03-13T17:52:29Z
dc.date.available2024-03-13T17:52:29Z
dc.date.issued2022-07-25
dc.identifier.issn1178-2005
dc.identifier.urihttp://hdl.handle.net/20.500.12613/9833
dc.description.abstractObjectives: In the IMPACT trial (NCT02164513), triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) showed clinical benefit compared with dual therapy with either FF/VI or UMEC/VI in the treatment of chronic obstructive pulmonary disease (COPD). We used data from IMPACT to determine whether this translated into differences in COPD-related healthcare resource utilization (HRU) costs in a United Kingdom (UK) setting. Methods: In a within-trial analysis, individual patient data from the IMPACT intention-to-treat (ITT) population were analyzed to estimate rates of COPD-related HRU with FF/UMEC/VI, FF/VI, or UMEC/VI. A Bayesian approach was applied to address issues typically encountered with this kind of data, namely data missing due to early study withdrawal, subjects with zero reported HRU, and skewness. Rates of HRU were estimated under alternate assumptions of data being missing at random (MAR) or missing not at random (MNAR). UK-specific unit costs were then applied to estimated HRU rates to calculate treatment-specific costs. Results: Under each MNAR scenario, per patient per year (PPPY) rates of COPD-related HRU were lowest amongst those patients who received treatment with FF/UMEC/VI compared with those receiving either FF/VI or UMEC/VI. Although absolute HRU rates and costs were typically higher for all treatment groups under MNAR scenarios versus MAR, final economic conclusions were robust to patient withdrawals. Conclusions: PPPY rates were typically lower with FF/UMEC/VI versus FF/VI or UMEC/VI.
dc.format.extent10 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartInternational Journal of Chronic Obstructive Pulmonary Disease, Vol. 17
dc.relation.isreferencedbyTaylor and Francis
dc.rightsAttribution-NonCommercial CC BY-NC
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectSingle-inhaler triple therapy
dc.subjectCOPD
dc.subjectHealthcare resource use
dc.subjectCost
dc.titleSingle-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
dc.typeText
dc.type.genreJournal article
dc.description.departmentThoracic Medicine and Surgery
dc.description.departmentMedicine
dc.relation.doihttp://dx.doi.org/10.2147/copd.s342244
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeLewis Katz School of Medicine
dc.temple.creatorCriner, Gerard J.
refterms.dateFOA2024-03-13T17:52:29Z


Files in this item

Thumbnail
Name:
CrinerEtAl-JournalArticle-2022 ...
Size:
531.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial CC BY-NC
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC